Node negative, T >5 cm

Fictional patient and quote.
*HR 0.666; 95% CI: 0.397–1.118. ARR=5.1%. Prespecified subgroup analysis, not powered to show significance. Median follow-up: 47.4 months. Data cut-off:
29 April 2024.¹
AJCC, American Joint Committee on Cancer; ARR, absolute risk reduction; CI, confidence interval; eBC, early breast cancer; ET, endocrine therapy;
ER, oestrogen receptor; HER2-, human epidermal growth factor receptor 2 negative; HR, hazard ratio; HR+, hormone receptor positive; IHC, immunohistochemistry; iDFS, invasive disease-free survival; N0, no nodal involvement; NS, non-significant; NSAI, non-steroidal aromatase inhibitor;
PR, progesterone receptor; T, tumour.

Node negative, T 2-5 cm, extra risks

Fictional patient and quote.
*Ki-67 ≥ 20%, or Oncotype DX Breast Recurrence Score ≥ 26, or high risk via genomic risk profiling.
**HR 0.666; 95% CI: 0.397–1.118. ARR=5.1%. Prespecified subgroup analysis, not powered to show significance. Median follow-up: 47.4 months. Data cut-off:
29 April 2024.¹
AJCC, American Joint Committee on Cancer; ARR, absolute risk reduction; CI, confidence interval; BC, breast cancer, eBC, early breast cancer; ER, oestrogen receptor; HR, hazard ratio; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; IHC, immunohistochemistry; iDFS, invasive disease-free survival; N0, no nodal involvement; NS, non-significant; NSAI, non-steroidal aromatase inhibitor; PR, progesterone receptor.

N1, T ≥5 cm

Fictional patient and quote.
*HR 0.731; 95% CI: 0.617–0.866. ARR=5.0%. Prespecified subgroup analysis, not powered to show significance. Median follow-up: 44.2 months. Data cut-off:
29 April 2024.¹
AJCC, American Joint Committee on Cancer; CI, confidence interval; eBC, early breast cancer, ER, oestrogen receptor; HR, hazard ratio; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; IHC, immunohistochemistry; N+, node positive; N1, 1-3 axillary lymph nodes; NSAI, non-steroidal aromatase inhibitor; PR, progesterone receptor; T, tumor.

N1, T <5 cm

Fictional patient and quote.
*Ki-67 ≥ 20%, or Oncotype DX Breast Recurrence Score ≥ 26, or high risk via genomic risk profiling.


**Stage IIB or stage IIA that is either N1 or N0 with: Grade 3 or grade 2 with additional risk factors, such as Ki-67 score of ≥20%, an Oncotype DX Breast Recurrence Score of ≥26, Prosigna PAM50, MammaPrint, or EndoPredict (EPclin) high-risk scores.^2,3

†HR 0.644; 95% CI: 0.468–0.887. ARR=4.3%. Prespecified subgroup analysis, not powered to show significance. Median follow-up: 47.4 months.
Data cut-off: 29 April 2024.¹

AJCC, American Joint Committee on Cancer; eBC, early breast cancer, ER, oestrogen receptor; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; IHC, immunohistochemistry; N0, node negative; N1, 1–3 axillary lymph nodes; NSAI, non-steroidal aromatase inhibitor;
PR, progesterone receptor; T, tumour.

N2, T2

Fictional patient and quote.
*HR 0.737; 95% CI: 0.611–0.888. ARR=5.9%. Prespecified subgroup analysis, not powered to show significance. Median follow-up: 38.7 months.
Data cut-off: 29 April 2024.¹
AJCC, American Joint Committee on Cancer; CI, confidence interval; eBC, early breast cancer; ER, oestrogen receptor; HER2-, human epidermal growth factor receptor 2 negative; R, hazard ratio; HR+, hormone receptor positive; IHC, immunohistochemistry; N2, 4-9 axillary lymph nodes; NSAI, non-steroidal aromatase inhibitor; PR, progesterone receptor; T2, tumour is more than 2 cm but less than 5 cm.